295 related articles for article (PubMed ID: 33661709)
1. Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting.
Tsai MJ; Cheng CK
Semin Ophthalmol; 2021 Apr; 36(3):132-138. PubMed ID: 33661709
[No Abstract] [Full Text] [Related]
2. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
3. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
Ozkaya A; Demir G; Kirmaci A
Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
[TBL] [Abstract][Full Text] [Related]
4. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.
Plaza-Ramos P; Borque E; García-Layana A
PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results.
Türkseven Kumral E; Erçalık NY
Semin Ophthalmol; 2021 Nov; 36(8):723-727. PubMed ID: 33760698
[TBL] [Abstract][Full Text] [Related]
8. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
[TBL] [Abstract][Full Text] [Related]
9. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
Salimi A; Vila N; Modabber M; Kapusta M
Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
Parca O; Cetin EN
Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study.
Isik P; Sizmaz S; Esen E; Uysal A; Demircan N
Int Ophthalmol; 2023 Nov; 43(11):4171-4180. PubMed ID: 37505290
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
14. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
Holbach B; Zeman F; Helbig H; Gamulescu MA
Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
[TBL] [Abstract][Full Text] [Related]
15. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE; Wasfy T; Shafik HM
BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
[TBL] [Abstract][Full Text] [Related]
16. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
[No Abstract] [Full Text] [Related]
17. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
19. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
[TBL] [Abstract][Full Text] [Related]
20. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]